National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

pelitrexol
A water soluble antifolate with anti-proliferative activity. Pelitrexol inhibits activity of glycinamide ribonucleotide formyltransferase (GARFT), the first folate-dependent enzyme of the de novo purine synthesis pathway essential for cell proliferation. Enzyme inhibition reduces the purine nucleotides pool required for DNA replication and RNA transcription. As a result, this agent causes cell cycle arrest in S-phase, and ultimately inhibits tumor cell proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:AG2037
Chemical structure names:
  • (2S)-2-[[[5-[2-[(6S)-2-amino-4-oxo-1,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophen-2-yl]carbonyl]amino]pentanedioic acid
  • L-glutamic acid,N-[[5-[2-[(6S)-2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methyl-2-thienyl]carbonyl]-



Previous:pegylated anti-GFR antibody fragment, pegylated granulocyte colony stimulating factor MAXY-G34, pegylated interferon alfa, pegylated irinotecan NKTR 102, pegylated liposomal doxorubicin hydrochloride
Next:pemetrexed disodium, Pen-Vee, penclomedine, penicillamine, penicillin V potassium

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov